Unidentified bright objects associated with features of neurofibromatosis 1

Pediatric Neurology

Volumn 27, Issue 2, 2002, Pages 123-127

  Szudek, Jacek ^a   Friedman, J M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE; ARTICLE; BRIGHTNESS; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE GLIOMA; PRIORITY JOURNAL; RISK;

ADOLESCENT; ADULT; BRAIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; NEUROFIBROMATOSIS 1;

EID: 0036696088     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(02)00403-4     Document Type: Article

References (14)

1. Griffiths P.D., Blaser S., Mukonoweshuro W., Armstrong D., Milo-Mason G., Cheung S. Neurofibromatosis bright objects in children with neurofibromatosis type 1: A proliferative potential? Pediatrics. 104:1999;e49.
2. DiMario F., Ramsby G. Magnetic resonance imaging lesion analysis in neurofibromatosis type 1. Arch Neurol. 55:1998;500-505.
3. DiPaolo D.P., Zimmerman R.A., Rorke L.B., Zackai E.H., Bilaniuk L.T., Yachnis A.T. Neurofibromatosis type 1: Pathologic substrate of high-signal-intensity foci in the brain. Radiology. 195:1995;721-724.
4. North K., Riccardi V., Samango-Sprouse C., et al. Cognitive function and academic performance in neurofibromatosis 1: Consensus statement from the NF1 Cognitive Disorders Task Force. Neurology. 48:1997;1121-1127.
5. Friedman J., Greene C., Birch P., NNFF International Database P. National Neurofibromatosis Foundation International Database. Am J Med Genet. 45:1993;88-91.
6. DeBella K., Poskitt K., Szudek J., Friedman J.M. Use of unidentified bright objects on MRI for diagnosis of neurofibromatosis 1 in children. Neurology. 54:2000;1646-1651.
7. Gutmann D., Aylsworth A., Carey J., et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 278:1997;51-57.
8. Zar J.H. More on dichotomous variables. Biostatistical analysis. 1999;565-568 Prentice Hall Upper Saddle River, NJ.
9. SAS Institute Inc. SAS software, version 6.12. 1996;SAS Institute Cary, NC.
10. DeBella K., Szudek J., Friedman J.M. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 105:2000;608-614.
11. McGaughran J.M., Harris D.I., Donnai D., et al. A clinical study of type 1 neurofibromatosis in north west England. J Med Genet. 36:1999;197-203.
12. Curless R., Siatkowski M., Glaser J., Shatz N. MRI diagnosis of NF-1 in children without café-au-lait skin lesions. Pediatr Neurol. 18:1998;269-271.
13. Gutmann D.H., Loehr A., Zhang Y., Kim J., Henkemeyer M., Cashen A. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene. 18:1999;4450-4459.
14. Friedman J., Birch P. An association between optic glioma and other tumors of the central nervous system in neurofibromatosis type 1. Neuropediatrics. 28:1997;131-132.